MGNX Macrogenics
- 4.260
- -0.105-2.41%
- 4.279
- +0.019+0.45%
Macrogenics News
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Bruker (BRKR)
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), MacroGenics (MGNX) and Alkermes (ALKS)
HC Wainwright & Co. : The Macrogenics (MGNX.US) rating was maintained, adjusted from neutral to neutral, and the target price was adjusted from $16.00 to $4.00.
HC Wainwright & Co. Maintains Neutral on Macrogenics, Lowers Price Target to $4
Macrogenics Analyst Ratings
Hold Rating on MacroGenics Amid Safety and Efficacy Concerns for Vobra Duo
Barclays: Maintaining the Macrogenics (MGNX.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $25.00 to $14.00.
Macrogenics Analyst Ratings
JMP Securities Maintains Market Outperform on Macrogenics, Lowers Price Target to $16
Stifel: Macrogenics (MGNX.US) rating downgraded from buy to hold, and target price adjusted from $29.00 to $7.00.
Macrogenics Analyst Ratings
Stifel Downgrades Macrogenics to Hold, Lowers Price Target to $7
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), Insmed (INSM) and MacroGenics (MGNX)
Buy Rating on MacroGenics: Promising Clinical Data and Market Position in MCRPC Treatment
Hold Rating on MacroGenics Amid TAMARACK Study Results and Competitive Concerns
B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
TD Cowen: Upgraded the Macrogenics (MGNX.US) rating from holding to buying.
Macrogenics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and MacroGenics (MGNX)
Analysis
Price Target
No Data
